HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial.

CAPRISA, 2017.Abstract available in pdf

Unadjusted Cox proportional hazards model for time to first CD4 ≤ 350 and time to composite disease progression endpoint.

<p>Unadjusted Cox proportional hazards model for time to first CD4 ≤ 350 and time to composite disease progression endpoint.</p

Linear mixed effects model comparing HIV-1 RNA (log₁₀) and CD4 T-cell counts between the first result 90 days or more after the estimated HIV seroconversion date (intercept) and the 12-month visit (slope) by study arm.

<p>Linear mixed effects model comparing HIV-1 RNA (log₁₀) and CD4 T-cell counts between the first result 90 days or more after the estimated HIV seroconversion date (intercept) and the 12-month visit (slope) by study arm.</p

MTN-015 study population of participants from MTN-003 parent protocol.

<p>MTN-015 study population of participants from MTN-003 parent protocol.</p